Arcera Life Sciences and Innogen Pharmaceuticals have formalized an exclusive licensing agreement designed to broaden the availability of innovative cardiometabolic treatments across multiple international territories. This strategic collaboration marks a pivotal advancement in Arcera’s efforts to reinforce its cardiometabolic franchise and diversify its portfolio of cutting-edge medicines.
The agreement leverages Innogen’s scientific expertise in metabolic diseases alongside Arcera’s strengths in regulatory affairs, market access, and commercialization. Under the terms, Arcera will oversee regulatory submissions, market access strategies, and commercialization activities for the licensed therapy across selected countries in Africa, Eastern Europe, Latin America, and the Middle East.
Innogen Pharmaceuticals will receive an upfront payment and is eligible for milestone payments and tiered royalties based on net sales within the licensed territories. This structure aligns incentives to support the therapy’s successful market introduction and growth.
Cardiometabolic diseases, including obesity and type 2 diabetes, represent a significant and escalating global health challenge. The International Diabetes Federation estimates that 589 million adults currently live with diabetes worldwide, a figure projected to rise to 853 million by 2050. This partnership aims to enhance patient access to advanced metabolic therapies that can address this growing burden.
Efsubaglutide Alfa, the licensed product, is a fusion protein combining a human GLP-1 analogue with an IgG Fc fragment, exhibiting a prolonged half-life of up to 280 hours in clinical studies. It belongs to the GLP-1 receptor agonist class, which is increasingly recognized for managing type 2 diabetes and obesity. In 2025, the World Health Organization included GLP-1 therapies in its Model List of Essential Medicines and issued global guidelines endorsing their use in obesity treatment.
Clinical trials have demonstrated Efsubaglutide Alfa’s efficacy and safety profile. In Chinese adults with overweight or obesity, 18 weeks of treatment resulted in average weight reductions of 10.6% with once-weekly dosing and 9.7% with once-every-two-weeks dosing. The therapy also improved body composition, increasing the muscle-to-fat ratio by up to 45.3%, primarily through fat mass reduction while preserving muscle. Liver fat content decreased by up to 51.8% with once-weekly dosing.
The incidence of gastrointestinal adverse events was comparatively low relative to other GLP-1 receptor agonists, with no treatment discontinuations due to adverse effects during the 18-week period. Innogen has further advanced clinical development with a Phase II trial in Australia assessing once-monthly dosing, generating additional data to support global registration and commercialization.
Isabel Afonso, Chief Executive Officer of Arcera Life Sciences, emphasized the significance of the collaboration: "Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve. Our agreement with Innogen accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio. By combining our partners’ scientific capabilities with Arcera’s regulatory expertise, market access and overall commercial reach, we aim to turn innovation into meaningful impact for people living with chronic disease.”
Dr. Qinghua Wang, Founder, Chairman, and Chief Executive Officer of Innogen Pharmaceuticals, added: "We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen’s international expansion. We believe that combining world-class science with entrepreneurial innovation is key to improving patient care. Innogen’s mission is to provide best-in-class and first-in-class therapies for people living with diabetes, obesity and other metabolic diseases worldwide. Our collaboration with Arcera is an important step toward this vision. By combining Innogen’s scientific innovation with Arcera’s strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world.”
The transaction remains subject to customary regulatory and operational approvals in the relevant jurisdictions. Commercial activities will commence following receipt of the necessary local regulatory authorizations.
Arcera Life Sciences, headquartered in Abu Dhabi, United Arab Emirates, operates across more than 60 direct markets spanning Africa, Eurasia, Latin America, and the Middle East. The company markets over 2,000 product presentations under 300+ brands and maintains manufacturing and packaging capabilities in eight countries. Arcera’s business model emphasizes partnerships with leading pharmaceutical and biotech firms to ensure supply resilience and quality standards.
Innogen Pharmaceuticals, founded in 2014 and listed on the Hong Kong Stock Exchange (HKEX: 2591), focuses on innovative medicines for metabolic diseases. Its pipeline includes treatments for type 2 and type 1 diabetes, obesity, metabolic dysfunction-associated steatohepatitis, and Alzheimer’s disease. Efsubaglutide Alfa, its flagship product, has been approved for type 2 diabetes treatment in mainland China and Macao and is included in China’s National Reimbursement Drug List (2025 version). The product’s development has been recognized with prestigious scientific awards and supported by China’s 13th Five-Year Plan Major New Drug Innovation program. Innogen’s manufacturing facilities hold PIC/S GMP certification, underscoring its commitment to global standards.
Arcera Life Sciences Secures Exclusive License from Innogen Pharmaceuticals to Advance Cardiometabolic Therapies Globally Arcera Life Sciences and Innogen Pharmaceuticals have entered an exclusive licensing agreement to commercialize Efsubaglutide Alfa, a next-generation GLP-1 receptor agonist, in selected international markets. This colla... Read the full IIPLA article: https://iipla.org/news/arcera-life-sciences-secures-exclusive-license-from-innogen-pharmaceuticals-to-advance-cardiometabolic-therapies-globally